Sat.Jul 03, 2021 - Fri.Jul 09, 2021

article thumbnail

UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing

pharmaphorum

The UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry. The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million re

article thumbnail

Medicenna takes on deadly brain cancer in clinical trial

Outsourcing Pharma

The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.

116
116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Collaboration & Agility – Core Themes & Lessons from Reuters Pharma USA 2021

Pharma Marketing Network

At this year’s Pharma USA conference, C ollaboration was the theme of the opening keynote session and a common thread woven throughout the event as industry leaders gathered to discuss how to move “Beyond Normal” to shape the future of health. In her opening statement, Izzy Gladstone, Reuters’ Head of Marketing, Pharma & Healthcare, challenged attendees to not return to our old ways of working.

article thumbnail

Is There a Link Between Low Testosterone and Depression?

Pharma Mirror

Testosterone is an essential hormone and steroid that affects many physiological functions. It is naturally more prevalent as an androgynous hormone in men, and it is therefore much more essential for them to have adequate amounts of it. However, with age, levels of this primary hormone can take a dive, usually for the worse. Symptoms of low testosterone may include weight gain, anxiety, low energy levels, low libido, insomnia, loss of concentration, and low mood.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Rare disease: industry, patients and tech join forces on diagnosis

pharmaphorum

Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can sometimes be the most difficult part of a rare disease patient’s journey, and it’s with good reason that the process is often referred to as an ‘odyssey’ in these communities. “We’re dealing with very small populations of patients, on top of small populations of specialist physicians who are able to diagnose them,” says Adam Zaeske, formerly head of Rare Diseases,

article thumbnail

Rare disease specialists talk resources, research and hope

Outsourcing Pharma

During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.

105
105

More Trending

article thumbnail

Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF

Pharma Times

Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients

63
article thumbnail

Imugene HER2 vaccine hits target in stomach cancer trial

pharmaphorum

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The interim readout from the 39-patient HERIZON trial found 50% of patients treated with the HER-Vaxx (IMU-131) vaccine on top of chemotherapy achieved a partial response or better, compared to 29% of patients given only chemo.

Vaccines 119
article thumbnail

Pharma SAAS solutions must balance safety, efficiency: IQVIA

Outsourcing Pharma

A leader from IQVIA suggests what to look for when seeking ways to automate drug safety processes, while maintaining security and customer satisfaction.

105
105
article thumbnail

SHSMD Connections 2021 | September 19-21 In Person | October 20-21 Virtual

Pharma Marketing Network

Join the Society for Health Care Strategy and Market Development (SHSMD) at their annual conference, SHSMD Connections 2021 this autumn. This annual conference is beneficial for health care strategists at any stage in their career that want to connect and learn from other industry professionals. Participants come from across the nation and possess a wide range of expertise about various facets of the health care strategy sector.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Oxford researchers launch HIV vaccine trial

Pharma Times

Vaccine will be evaluated in 13 HIV-negative adults aged 18-65 years old

article thumbnail

Gates Foundation backs COVID R&D at AI firm Exscientia

pharmaphorum

Artificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an award by the Bill & Melinda Gates Foundation. . The $1.5 million grant will be used to develop a new class of small-molecule inhibitors of M pro , a protease enzyme essential for the replication of the SARS-CoV-2 virus.

Vaccines 111
article thumbnail

Duke University, HumanFirst partner to assess digital clinical measuring tools

Outsourcing Pharma

The two entities will work together to evaluate digital sensors and other tools used in clinical research, checking the items for accuracy and equity.

98
article thumbnail

Dextromethorphan Clinical Pearls

Med Ed 101

In this article, we’d like to share some of the most common dextromethorphan clinical pearls that you should be aware of. Dextromethorphan (DXM) is an over-the-counter medication often found in many of the Robitussin products, among others. It is approved to treat cough in adults and children 12 and older. Relief starts 15-30 minutes after […].

40
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Kuano raises £1m to further develop AI drug discovery platform

Pharma Times

Company is aiming to transform the discovery of therapeutics focused on enzyme inhibition

58
article thumbnail

EMA finds possible link between mRNA COVID jabs and myocarditis

pharmaphorum

The EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based vaccines for COVID-19 and rare cases of heart inflammation. . According to the EMA’s pharmacovigilance risk assessment committee (PRAC), labelling for Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax should be updated to reflect “very rare cases” of myocarditis and pericarditis with the shots.

Vaccines 105
article thumbnail

CRO Parexel to be acquired by Goldman Sachs in $8.5b deal

Outsourcing Pharma

The global contract research organization has announced it will be purchased by Goldman Sachs Asset Management and EQT Private Equity.

81
article thumbnail

Questions You Need to Ask Your Pharmacist

Lifewell Rx Pharmacy

Pharmacists from your community pharmacy in Kentucky are the most approachable healthcare professionals you can talk to. As medication experts you can trust, they can answer your questions regarding your care plan, medications, and disease management. This may include explaining how to take your medication or providing more information about a disease to enhance your health.

article thumbnail

Merck partners with Innervia on bioelectronic therapy development

Pharma Times

Collaboration will focus on the development of smart neurostimulators for the treatment of severe chronic diseases

53
article thumbnail

NICE rejects Orchard’s gene therapy for rare childhood disease MLD

pharmaphorum

Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance. The agency said that while there was evidence of a short-term benefit with Libmeldy (atidarsagene autotemcel or OTL-200 ), assumptions about its long-term effects are uncertain, making it unclear whether it will offer value for money to the NHS.

article thumbnail

People on the Move: July 2021

Outsourcing Pharma

This monthâs news on hires, promotions, acquisitions, and expansions includes items about Javara, Elligo, Lonza, Yourway, Medable, and other notable firms.

52
article thumbnail

GSK cancer head Hoos exits, takes top role at biotech Scorpion

pharmaphorum

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . Hoos is leaving GSK after nine years, a period that saw a complete revamp of the unit including the wholesale divestment of cancer drugs to Novartis in a $16 billion deal announced in 2014 – which completed as he took over the division.

article thumbnail

Novartis tries to rescue stalled inclisiran filing with FDA

pharmaphorum

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug. The US regulator issued Novartis with a complete response letter (CRL) for inclisiran in December, citing “unresolved facility inspection-related conditions” at a third-party manufacturing site run by Corden Pharma near Milan, Italy.

FDA 105
article thumbnail

FDA rejects Provention’s type 1 diabetes drug teplizumab

pharmaphorum

The FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in April when it delayed its review. Now, the agency has rejected the application entirely, sending the company’s shares into a steep slide. The complete response letter (CRL) for teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals reiterates the FDA’s concerns around the pharmacokinetics (PK) data for the antibody.

FDA 98
article thumbnail

Another hurdle down as EU clears AstraZeneca’s Alexion takeover

pharmaphorum

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across the line. The EU approval comes after the merger has already been okayed by the US, Japan and a number of other countries around the world, and AZ says it is now hoping to completing the transaction by the end of this quarter.

article thumbnail

Performance.io appoints Jason Brown as global chief commercial officer

pharmaphorum

UK-based online marketing agency Performance.io (PIO) has appointed Jason Brown as it’s global chief commercial officer. Brown has held several senior leadership positions at pharma companies including Sanofi and Novartis, before joining sales force benchmarking organisation, STEM where he was promoted to President of EU5 and global COO. His most recent role was as chief commercial officer at Pharmaspectra, where he was responsible for the company’s international growth.

76
article thumbnail

Pharma execs join DigitalEurope’s new health council

pharmaphorum

Senior figures from GlaxoSmithKline, Roche, Bayer, and Johnson & Johnson have been named to an 18-strong executive council for health at DigitalEurope – a trade association representing the tech industry. The new council has been set up to help drive the adoption of digital approaches that could help deliver personalised care, improve disease monitoring and prevention, and potentially reduce costs for health systems across Europe.

article thumbnail

Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

pharmaphorum

Four years after being taken private, Parexel has been sold again, with Goldman Sachs’ private equity arm and EQT paying $8.5 billion to claim ownership of the contract research organisation. The handover comes four years after Pamplona Capital Management bought the company for around $5 billion, and just a few weeks after lab tech company Thermo Fisher Scientific agreed to acquire another CRO – PPD – in a deal valued at $17.4 billion.

article thumbnail

Sonde Health partners with Qualcomm on vocal biomarker tech

pharmaphorum

Sonde Health has joined forces with chipmaker Qualcomm to develop a technology platform that could diagnose human health conditions from a short sample of speech. . The two companies will make sure that Sonde Health’s vocal biomarker platform is optimised for use with Qualcomm chips used to power 5G mobile devices, saying this could unlock a number of health screening and monitoring applications.

59
article thumbnail

A life sciences vision to deliver health, wealth and resilience for the UK

pharmaphorum

The ABPI’ s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19. What has been achieved in just 18 months is nothing short of remarkable.

article thumbnail

Dementia, cancer headline UK’s 10-year plan for life sciences sector

pharmaphorum

The UK’s long-awaited Life Sciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep the country at the forefront of the sector. The document published today lays out seven healthcare “missions” for the UK’s industry as it tries to double down on the success of the COVID-19 response, and solve some of the biggest healthcare problems such as cancer and dementia.

article thumbnail

Unsure whether to get a COVID-19 jab? Just ask Vira!

pharmaphorum

With COVID-19 vaccine hesitance an increasing concern in the US, researchers at Johns Hopkins have developed a chatbot – called Vira – that aims to explode myths about vaccination. Worried that COVID-19 vaccines have serious side effects that are being covered up, or vaccines are being used to track the population? Or just uncertain whether you should be vaccinated as en expectant mother, or if you can choose which vaccine you receive?

article thumbnail

Almirall kicks off another hunt for skin disease therapy partnerships

pharmaphorum

Spanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its core area of expertise. The latest edition of its AlmirallShare competition – which will take submissions until 31 October this year – is hunting for innovative therapies for skin diseases that are in the research or preclinical development stage.

article thumbnail

Performance.io appoints Jason Brown as global chief commercial officer

pharmaphorum

UK-based online marketing agency Performance.io (PIO) has appointed Jason Brown as it’s global chief commercial officer. Brown has held several senior leadership positions at pharma companies including Sanofi and Novartis, before joining sales force benchmarking organisation, STEM where he was promoted to President of EU5 and global COO. His most recent role was as chief commercial officer at Pharmaspectra, where he was responsible for the company’s international growth.

52